Epigenetic Reprogramming of Monocytes in Patients With Coronary Atherosclerosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02393768

Enrollment

Registered

2015-03-19

Start date

2014-10-31

Completion date

2015-12-31

Last updated

2016-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Brief summary

In this study, the investigators will determine whether patients with documented atherosclerosis are characterized by specific epigenetic changes in circulating cells of the innate immune system, compared to patients without atherosclerosis.

Detailed description

Rationale: The innate immune system plays a pivotal role in the development and progression of atherosclerosis. Recently, it was reported that monocytes can develop a long-lasting immunological memory after stimulation with various microorganisms, which has been termed 'trained innate immunity'. This memory is induced by epigenetic reprogramming. We hypothesize that trained monocytes augment atherogenesis. Objective: The main objective is to study whether patients with coronary atherosclerosis show specific epigenetic changes in the promoter regions of pro-inflammatory cytokines and chemokines and whether this correlates with the inflammatory phenotype of these cells. Study design: Observational study Study population: Adult patients who have had computed tomography coronary angiography because of chest pain: 20 patients without atherosclerosis and 20 patients with severe atherosclerosis will be included.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients (male/female), * aged \>18 years, * admitted to the acute coronary unit of the CWZ hospital for evaluation of chest pain. * No coronary atherosclerosis * Or Severe atherosclerosis

Exclusion criteria

* Signs or symptoms of a current infection (fever, chills) * Auto-immune diseases (such as rheumatoid arthritis)

Design outcomes

Primary

Measure	Time frame
Epigenetic modifications in circulating monocytes	baseline

Secondary

Measure	Time frame
Inflammatory phenotype	baseline

Countries

Netherlands

Outcome results